BioChem Pharma Inc. (BCHXF)
Scotia McLeod analyst Claude Proulx recommended that investors buy on weakness. He rates the stock a hold and would buy below $12, with a target price of $15 if results from studies of BCHXF's 3TC reverse transcriptase inhibitor (RTI) in hepatitis B are good. Phase I/II